The Evolution of Percutaneous Mitral Valve Repair Therapy

Abstract Mitral regurgitation (MR) is the most common valve disease in the United States. However, a significant number of patients are denied surgery due to increased age, poor ventricular function, or associated comorbidities, putting them at high risk for adverse events. Moreover, the benefit of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2014-12, Vol.64 (24), p.2688-2700
Main Authors: Beigel, Roy, MD, Wunderlich, Nina C., MD, Kar, Saibal, MD, Siegel, Robert J., MD
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular
Internal Medicine
Logistics
Medical prognosis
mitral valve
mitral valve annuloplasty
mitral valve insufficiency
Mortality
outcomes assessment
patient selection
Pulmonary arteries
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Mitral regurgitation (MR) is the most common valve disease in the United States. However, a significant number of patients are denied surgery due to increased age, poor ventricular function, or associated comorbidities, putting them at high risk for adverse events. Moreover, the benefit of surgery for MR is unclear in patients with functional (secondary) MR. Recently, percutaneous repair of the mitral valve with a particular device (MitraClip, Abbott, Menlo Park, California) has emerged as a novel therapeutic option for patients with secondary MR or those deemed to be high risk for surgery. We review data from its initial concept through clinical trials and current data available from several registries. We focused on lessons learned regarding adequate patient selection, along with current and future perspectives on the use of device therapy for the treatment of MR.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2014.08.049